ArticleJournal of computer-aided molecular design2025
Integrated computational and experimental evaluation of grossamide as a natural product scaffold for dual carbohydrase inhibition in diabetes.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the widespread use of Grossamide-containing plants in traditional medicine and its documented anti-inflammatory and metabolic regulatory properties, this lignanamide's potential as an antidiabetic agent remains unexplored. Current α-glucosidase inhibitors like acarbose suffer from poor patient compliance due to severe gastrointestinal side effects, creating an urgent need for better-tolerated alternatives. This study investigated whether Grossamide's unique structural features and established bioactivities could translate into clinically relevant carbohydrase inhibition. Through integrated computational and experimental approaches, we demonstrate that Grossamide exhibits potent dual inhibition of α-amylase (IC
Indexed as
Identifiers
41212441What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.